

Endocrine Therapy in Breast Cancer

Adjuvant

Premenopausal – Tamoxifen 5 years

Postmenopausal – Anastrozole 5 years (consider prescribing for 10 years for high risk patients who are tolerating treatment)

Premenopausal at diagnosis who become postmenopausal (chemotherapy or surgery – induced menopause) – at time of becoming postmenopausal switch from tamoxifen to anastrozole (5 years)

Metastatic

Premenopausal

First line - Tamoxifen

Second line – Zoladex +/- anastrozole

Third line – Zoladex +/- exemestane (+/- everolimus [CDF])

Fourth line – Zoladex +/- fulvestrant

Postmenopausal

First line - Anastrozole

Second line – Tamoxifen

Third line – Exemestane (+/- everolimus [CDF])

Fourth line – Fulvestrant (after tamoxifen and at least one AI, so could be 3rd line)

Premenopausal use of Aromatase Inhibitors

Indicated if funding approval for zoledronic acid

Zoladex +/- Anastrozole +/- Zoledronic acid